1. Besedovsky H, Sorkin E, Felix D, Haas H. Hypothalamic changes during the immune response. Eur J Immunol. 1977;7:323–5. [PubMed]
2. Klimenko VM. Handbook of immunophysiology. St Petersburg: Nauka; 1993. Neurophysiological analysis of nervous–immune systems relationship; pp. 67–200.
3. Besedovsky HO, Sorkin E, Keller M, Müller J. Changes in blood hormone levels during the immune response. Proc Soc Exp Biol Med. 1975;150:466–70. [PubMed] 4. Besedovsky HO, del Rey AE, Sorkin E, Da Prada M, Burri R, Honegger C. The immune response evokes changes in brain noradrenergic neurons. Science. 1983;221:564–6. [PubMed] 5. Besedovsky HO, del Rey A, Sorkin E. Lymphokine-containing supernatants from Con A-stimulated cells increase corticosterone blood levels. J Immunol. 1981;126:385–7. [PubMed] 6. Besedovsky HO, del Rey A, Sorkin E, Dinarello CA. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science. 1986;233:652–4. [PubMed] 7. Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev. 1996;17:64–102. [PubMed] 8. Dunn AJ. Systemic interleukin-1 administration stimulates hypothalamic norepinephrine metabolism parallelling the increased plasma corticosterone. Life Sci. 1988;43:429–35. [PubMed] 9. Kabiersch A, del Rey A, Honegger CG, Besedovsky HO. Interleukin-1 induces changes in norepinephrine metabolism in the rat brain. Brain Behav Immun. 1988;2:267–74. [PubMed] 10. Feldmann M. What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis? Int Arch Allerg Immunol. 1996;111:362–5. [PubMed] 11. Plotsky PM, Cunningham ET, Widmaier EP. Catecholaminergic modulation of corticotropin-releasing factor and adrenocorticotropin secretion. Endocr Rev. 1989;10:437–58. [PubMed] 12. Zalcman S, Green-Johnson JM, Murray L, et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 1994;643:40–9. [PubMed] 13. Kaur D, Cruess DF, Potter WZ. Effect of IL-1α on the release of norepinephrine in rat hypothalamus. J Neuroimmunol. 1998;90:122–7. [PubMed] 14. Smagin GN, Swiergiel AH, Dunn AJ. Peripheral administration of interleukin-1 increases extracellular concentrations of norepinephrine in rat hypothalamus: comparison with plasma corticosterone. Psychoneuroendocrinology. 1996;21:83–93. [PubMed] 15. Ishizuka Y, Ishida Y, Kunitake T, et al. Effects of area postrema lesion and vagotomy on interleukin-1β-induced norepinephrine release in the hypothalamic paraventricular nucleus region in the rat. Neurosci Lett. 1997;223:57–60. [PubMed] 16. Merali Z, Lacosta S, Anisman H. Effects of interleukin-1β and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: a regional microdialysis study. Brain Res. 1997;761:225–35. [PubMed] 17. Wieczorek M, Dunn AJ. Relationships among the behavioral, noradrenergic and pituitary-adrenal responses to interleukin-1 and the effects of indomethacin. Brain Behav Immun. 2006;20 in press. [PMC free article] [PubMed] 18. MohanKumar PS, Quadri SK. Systemic administration of interleukin-1 stimulates norepinephrine release in the paraventricular nucleus. Life Sci. 1993;52:1961–7. [PubMed] 19. Terao A, Oikawa M, Saito M. Cytokine-induced change in hypothalamic norepinephrine turnover: involvement of corticotropin-releasing hormone and prostaglandins. Brain Res. 1993;622:257–61. [PubMed] 20. Fleshner M, Goehler LE, Hermann J, Relton JK, Maier SF, Watkins LR. Interleukin-1β induced corticosterone elevation and hypothalamic NE depletion is vagally mediated. Brain Res Bull. 1995;37:605–10. [PubMed] 21. MohanKumar SMJ, MohanKumar PS, Quadri SK. Specificity of interleukin-1β-induced changes in monoamine concentrations in hypothalamic nuclei: blockade by interleukin-1 receptor antagonist. Brain Res Bull. 1998;47:29–34. [PubMed] 22. Abreu P, Llorente E, Hernández MM, González MC. Interleukin-1β stimulates tyrosine hydroxylase activity in the median eminence. Neuroreport. 1994;5:1356–8. [PubMed] 23. Kabiersch A, Furukawa H, del Rey A, Besedovsky HO. Administration of interleukin-1 at birth affects dopaminergic neurons in adult mice. Ann NY Acad Sci. 1998;840:123–7. [PubMed] 24. Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science. 1993;261:472–5. [PubMed] 25. Johnson RW, Curtis SE, Dantzer R, Kelley KW. Central and peripheral prostaglandins are involved in sickness behavior in birds. Physiol Behav. 1993;53:127–31. [PubMed] 26. Dunn AJ. Endotoxin-induced activation of cerebral catecholamine and serotonin metabolism: comparison with interleukin-1. J Pharmacol Exp Ther. 1992;261:964–9. [PubMed] 27. Uehara A, Gottschall PE, Dahl RR, Arimura A. Stimulation of ACTH release by human interleukin-1β, but not by interleukin-1α, in conscious, freely moving rats. Biochem Biophys Res Commun. 1987;146:1286–90. [PubMed] 28. Matta SG, Linner KM, Sharp BM. Interleukin-1-α and interleukin-1-β stimulate adrenocorticotropin secretion in the rat through a similar hypothalamic receptor(s): effects of interleukin-1 receptor antagonist protein. Neuroendocrinology. 1993;57:14–22. [PubMed]
29. Liu C, Takao T, Hashimoto K, De Souza EB. Interleukin-1 receptors in the nervous system. In: Rothwell NJ, editor. Cytokines in the Nervous System. Austin, Texas: R.G Landes Company; 1996. pp. 21–40.
30. Dunn AJ, Chuluyan H. The role of cyclo-oxygenase and lipoxygenase in the interleukin-1-induced activation of the HPA axis: dependence on the route of injection. Life Sci. 1992;51:219–25. [PubMed] 31. Terao A, Kitamura H, Asano A, Kobayashi M, Saito M. Roles of prostaglandins D2 and E2 in interleukin-1-induced activation of norepinephrine turnover in the brain and peripheral organs of rats. J Neurochem. 1995;65:2742–7. [PubMed] 32. Swiergiel AH, Dunn AJ. CRF-deficient mice respond like wild type mice to hypophagic stimuli. Pharmacol Biochem Behav. 1999;64:59–64. [PubMed]
33. Wieczorek M, Dunn AJ. The role of the vagus nerve in the febrile, behavioral, noradrenergic and endocrine responses to interleukin-1β in the rat. Brain Res. submitted.
34. Wieczorek M, Pournajafi-Nazarloo H, Swiergiel AH, Dunn A. Physiological and behavioral responses to interleukin-1b and LPS in vagotomized mice. Physiol Behav. 2005;84:500–11. [PMC free article] [PubMed]
35. Dunn AJ. Nitric oxide synthase inhibitors prevent the cerebral tryptophan and serotonergic responses to endotoxin and interleukin-1. Neurosci Res Commun. 1993;13:149–56.
36. Dunn A. The role of nitric oxide in the indoleaminergic responses to IL-1 and LPS. Brain Behav Immun. 2002;16:180.
37. Dunn AJ. unpublished observations
38. Dunn AJ, Chuluyan HE. Endotoxin elicits normal tryptophan and indolamine responses but impaired catecholamine and pituitary–adrenal responses in endotoxin-resistant mice. Life Sci. 1994;54:847–53. [PubMed] 39. Tagliamonte A, Tagliamonte P, Perez-Cruet J, Stern S, Gessa GL. Effect of psychotropic drugs on tryptophan concentration in rat brain. J Pharmacol Exp Ther. 1971;177:475–80. [PubMed] 40. Chaouloff F. Physiopharmacological interactions between stress hormones and central serotonergic systems. Brain Res Rev. 1993;18:1–32. [PubMed] 41. Curzon G, Joseph MH, Knott PJ. Effects of immobilization and food deprivation on rat brain tryptophan metabolism. J Neurochem. 1972;19:1967–74. [PubMed] 42. Dunn AJ. Changes in plasma and brain tryptophan and brain serotonin and 5-hydroxyindoleacetic acid after footshock stress. Life Sci. 1988;42:1847–53. [PubMed] 43. Dunn AJ, Welch J. Stress- and endotoxin-induced increases in brain tryptophan and serotonin metabolism depend on sympathetic nervous system activation. J Neurochem. 1991;57:1615–22. [PubMed] 44. Lookingland KJ, Shannon NJ, Chapin DS, Moore KE. Exogenous tryptophan increases synthesis, storage, and intraneuronal metabolism of 5-hydroxytryptamine in the rat hypothalamus. J Neurochem. 1986;47:205–12. [PubMed] 45. Joseph MH, Kennett GA. Stress-induced release of 5-HT in the hippocampus and its dependence on increased tryptophan availability: an in vivo electrochemical study. Brain Res. 1983;270:251–7. [PubMed] 46. De Simoni MG, Sokola A, Fodritto F, Dal Toso G, Algeri S. Functional meaning of tryptophan-induced increase of 5-HT metabolism as clarified by in vivo voltammetry. Brain Res. 1987;411:89–94. [PubMed] 47. Edwards DJ, Sorisio DA, Knopf S. Effects of the β2-adrenoceptor agonist clenbuterol on tyrosine and tryptophan in plasma and brain of the rat. Biochem Pharmacol. 1989;38:2957–65. [PubMed] 48. Lenard NR, Gettys TW, Dunn AJ. Activation of β2- and β3- adrenergic receptors increases brain tryptophan. J Pharmacol Exp Ther. 2003;305:653–9. [PubMed] 49. Rada P, Mark GP, Vitek MP, et al. Interleukin-1β decreases acetylcholine measured by microdialysis in the hippocampus of freely moving rats. Brain Res. 1991;550:287–90. [PubMed] 50. Kang M, Yoshimatsu H, Ogawa R, et al. Thermoregulation and hypothalamic histamine turnover modulated by interleukin-1 beta in rats. Brain Res Bull. 1994;35:299–301. [PubMed] 51. Niimi M, Mochizuki T, Yamamoto Y, Yamatodani A. Interleukin-1 beta induces histamine release in the rat hypothalamus in vivo. Neurosci Lett. 1994;181:87–90. [PubMed] 52. Bianchi M, Ferrario P, Zonta N, Panerai AE. Effects of interleukin-1β and interleukin-2 on amino acids levels in mouse cortex and hippocampus. NeuroReport. 1995;6:1689–92. [PubMed] 53. Mascarucci P, Perego C, Terrazzino S, De Simoni M. Glutamate release in the nucleus tractus solitarius induced by peripheral lipolysaccharide and interleukin-1β Neuroscience. 1998;86:1285–90. [PubMed] 54. Veening JG, van der Meer MJM, Joosten H, et al. Intravenous administration of interleukin-1β induces fos-like immunoreactivity in corticotropin-releasing hormone neurons in the paraventricular hypothalamic nucleus of the rat. J Chem Neuroanat. 1993;6:391–7. [PubMed] 55. Chang SL, Ren T, Zadina JE. Interleukin-1 activation of Fos protooncogene protein in the rat hypothalamus. Brain Res. 1993;617:123–30. [PubMed] 56. Ericsson A, Kovács KJ, Sawchenko PE. A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J Neurosci. 1994;14:897–913. [PubMed] 57. Brady LS, Lynn AB, Herkenham M, Gottesfeld Z. Systemic interleukin-1 induces early and late patterns of c-fos mRNA expression in brain. J Neurosci. 1994;14:4951–64. [PubMed] 58. Day HEW, Akil H. Differential pattern of c-fos mRNA in rat brain following central and systemic administration of interleukin-1-beta: implications for mechanism of action. Neuroendocrinology. 1996;63:207–18. [PubMed] 59. Rivest S, Rivier C. Stress and interleukin-1β-induced activation of c-fos, NGFI-B and CRF gene expression in the hypothalamic PVN: comparison between Sprague-Dawley, Fisher-344 and Lewis rats. J Neuroendocrinol. 1994;6:101–17. [PubMed] 60. Swiergiel AH, Dunn AJ, Stone EA. The role of cerebral noradrenergic systems in the Fos response to interleukin-1. Brain Res Bull. 1996;41:61–4. [PubMed] 61. Williams LM, Ballmer PE, Hannah LT, Grant I, Garlick PJ. Changes in regional protein synthesis in rat brain and pituitary after systemic interleukin-1β administrations. Am J Physiol. 1994;267:E915–E20. [PubMed] 62. Anisman H, Kokkinidis L, Merali Z. Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation. Brain Res. 1996;731:1–11. [PubMed] 63. Pettito JM, McCathy DB, Rinker C, Hunag Z, Getty T. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J Neuroimmunol. 1997;73:183–90. [PubMed] 64. Song C, Leonard BE. Interleukin-2-induced changes in behavioural, neurotransmitter, and immunological parameters in the olfactory bulbectomized rat. Neuroimmunomodulation. 1995;2:263–73. [PubMed] 65. Pauli S, Linthorst AC, Reul JM. Tumour necrosis factor-α and interleukin-2 differentially affect hippocampal serotonergic neurotransmission, behavioural activity, body temperature and hypothalamic-pituitary-adrenocortical axis activity in the rats. Eur J Neurosci. 1998;10:868–78. [PubMed] 66. Lacosta S, Merali Z, Anisman H. Central monoamine activity following acute and repeated systemic interleukin-2 administration. Neuroimmunomodulation. 2000;8:83–90. [PubMed] 67. Brown RR, Lee MC, Kohler PC, Hank JA, Storer BE, Sondel PM. Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin-2. Cancer Res. 1989;49:4941–4. [PubMed] 68. Raber J, Koob GF, Bloom FE. Interleukin-2 (IL-2) induces corticotropin-releasing factor (CRF) release from the amygdala and involves a nitric oxide-mediated signaling; comparison with the hypothalamic response. J Pharmacol Exp Ther. 1995;272:815–24. [PubMed] 69. Lapchak PA. A role for interleukin-2 in the regulation of striatal dopaminergic function. NeuroReport. 1992;3:165–8. [PubMed] 70. Lapchak PA, Araujo DM. Interleukin-2 regulates monoamine and opioid peptide release from the hypothalamus. NeuroReport. 1993;4:303–6. [PubMed] 71. Wang JP, Dunn AJ. Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem Int. 1998;33:143–54. [PubMed]
72. Dunn A. Cytokine activation of the hypothalamo–pituitary–adrenal axis. In: Steckler T, Kalin N, Reul JMHM, editors. Handbook of stress and the brain part 2: stress: integrative and clinical aspects. Vol. 15. Amsterdam: Elsevier; 2005. pp. 157–74.
73. Barkhudaryan N, Dunn AJ. Molecular mechanisms of actions of interleukin-6 on the brain, with special reference to serotonin and the hypothalamo–pituitary–adrenocortical axis. Neurochem Res. 1999;24:1169–80. [PubMed] 74. Zhang J-J, Terreni L, De Simoni M-G, Dunn AJ. Peripheral interleukin-6 administration increases extracellular concentrations of serotonin and the evoked release of serotonin in the rat striatum. Neurochem Int. 2001;38:303–8. [PubMed] 75. Wu Y, Shaghaghi EK, Jacquot C, Pallardy M, Gardier AM. Synergism between interleukin-6 and interleukin-1β in hypothalamic serotonin release: a reverse in vivo microdialysis study in F344 rats. Eur Cytokine Netw. 1999;10:57–64. [PubMed] 76. Wang JP, Dunn AJ. The role of interleukin-6 in the activation of the hypothalamo-pituitary–adrenocortical axis induced by endotoxin and interleukin-1β Brain Res. 1999;815:337–48. [PubMed]
77. Swiergiel AH, Dunn AJ. Behavioral, neurochemical and endocrine responses in mice lacking the gene for IL-6. Behav Brain Res. in press.
78. Niimi M, Wada Y, Sato M, Takahara J, Kawanishi K. Effect of continuous intravenous injection of interleukin-6 and pretreatment with cyclooxygenase inhibitor on brain c-fos expression in the rat. Neuroendocrinology. 1997;66:47–53. [PubMed] 79. Callahan TA, Piekut DT. Differential Fos expression induced by IL-1β and IL-6 in rat hypothalamus and pituitary gland. J Neuroimmunol. 1997;73:207–11. [PubMed]
80. Tinsley SL, Knight D, Dunn AJ. The effects of interleukin-6 on Fos expression in the rat brain. Soc Neurosci Abstr. 2001;27:1749.
81. Fransen L, Müller R, Marmenout A, et al. Molecular cloning of mouse tumor necrosis factor cDNA and its eukaryotic expression. Nucleic Acids Res. 1985;13:4417–29. [PMC free article] [PubMed] 82. Sherry B, Jue DM, Zentella A, Cerami A. Characterization of high molecular weight glycosylated forms of murine tumor necrosis factor. Biochem Biophys Res Commun. 1990;173:1072–8. [PubMed] 83. Lewis M, Tartaglia LA, Lee A, et al. Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. Proc Natl Acad Sci USA. 1991;88:2830–4. [PubMed] 84. Brouckaert P, Libert C, Everaerdt B, Fiers W. Selective species specificity of tumor necrosis factor for toxicity in the mouse. Lymphokin Cytokine Res. 1992;11:193–6. [PubMed] 85. Michie HR, Spriggs DR, Manogue KR, et al. Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery. 1988;104:280–6. [PubMed] 86. Besedovsky HO, del Rey A, Klusman I, Furukawa H, Monge Arditi G, Kabiersch A. Cytokines as modulators of the hypothalamus–pituitary–adrenal axis. J Steroid Biochem Mol Biol. 1991;40:613–8. [PubMed] 87. Perlstein RS, Whitnall MH, Abrams JS, Mougey EH, Neta R. Synergistic roles of interleukin-6, interleukin-1, and tumor necrosis factor in the adrenocorticotropin response to bacterial lipopolysaccharide in vivo. Endocrinology. 1993;132:946–52. [PubMed] 88. Sharp BM, Matta SG. Prostaglandins mediate the adrenocorticotropin response to tumor necrosis factor in rats. Endocrinology. 1993;132:269–74. [PubMed] 89. del Rey A, Besedovsky HO. Metabolic and neuroendocrine effects of pro-inflammatory cytokines. Eur J Clin Invest. 1992;22(Suppl 1):10–15. [PubMed] 90. Dunn AJ. The role of interleukin-1 and tumor necrosis factor α in the neurochemical and neuroendocrine responses to endotoxin. Brain Res Bull. 1992;29:807–12. [PubMed] 91. Sharp BM, Matta SG, Peterson PK, Newton R, Chao C, McAllen K. Tumor necrosis factor-α is a potent ACTH secretagogue: comparison to interleukin-1β Endocrinology. 1989;124:313–13. [PubMed] 92. Ando T, Dunn AJ. Mouse tumor necrosis factor-α increases brain tryptophan concentrations and norepinephrine metabolism while activating the HPA axis in mice. Neuroimmunomodulation. 1999;6:319–29. [PubMed] 93. Hayley S, Kelly O, Anisman H. Corticosterone changes in response to stressors, acute and protracted actions of tumor necrosis factor-α and lipopolysaccharide treatments in mice lacking the tumor necrosis factor-α p55 receptor gene. Neuroimmunomodulation. 2004;11:241–6. [PubMed] 94. Hayley S, Brebner K, Lacosta S, Merali Z, Anisman H. Sensitization to the effects of tumor necrosis factor-α: neuroendocrine, central monoamine, and behavioral variations. J Neurosci. 1999;19:5654–65. [PubMed] 95. Hayley S, Staines W, Merali Z, Anisman H. Time-dependent sensitization of corticotropin-releasing hormone, arginine vasopressin and c-fos immunoreactivity within the mouse brain in response to tumor necrosis factor-α Neuroscience. 2001;106:137–48. [PubMed] 96. Anisman H, Merali Z, Hayley S. Sensitization associated with stressors and cytokine treatments. Brain Behav Immun. 2003;17:86–93. [PubMed] 97. Elenkov IJ, Kovacs K, Duda E, Stark E, Vizi ES. Presynaptic inhibitory effect of TNF-α on the release of noradrenaline in isolated median eminence. J Neuroimmunol. 1992;413:117–20. [PubMed] 98. Ignatowski TA, Spengler RN. Tumor necrosis factor-α: presynaptic sensitivity is modified after antidepressant drug adminstration. Brain Res. 1994;665:293–9. [PubMed] 99. Hurst SM, Collins SM. Mechanism underlying tumor necrosis factor-α suppression of norepinephrine release from rat myenteric plexus. Am J Physiol. 1994;266:G1123–G9. [PubMed] 100. Foucart S, Abadie C. Interleukin-1β and tumor necrosis factor-α inhibit the release of [3H]-noradrenaline from mice isolated atria. NS Arch Pharmacol. 1996;354:1–6. [PubMed] 101. Schaefer M, Schwaiger M, Pich M, Lieb K, Heinz A. Neurotransmitter changes by interferon-alpha and therapeutic implications. Pharmacopsychiatry. 2003;36(Suppl 3):S203–S6. [PubMed] 102. Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R. Repeated interferon-α administration inhibits dopaminergic neural activity in the mouse brain. Brain Res. 1997;747:348–51. [PubMed] 103. Kumai TTT, Tanaka M, Watanabe M, Shimizu H, Kobayashi S. Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats. Life Sci. 2000;67:663–9. [PubMed]
104. Dunn AJ. Effects of cytokines and infections on brain neurochemistry. In: Ader R, Felten DL, Cohen N, editors. Psychoneuroimmunology. New York: Academic Press; 2001. pp. 649–66.
105. Segall MS, Crnic LS. An animal model for the behavioral effects of interferon. Behav Neurosci. 1990;104:612–8. [PubMed] 106. Crnic LS, Segall MA. Behavioral effects of mouse interferon-α and interferon-γ and human interferon-α in mice. Brain Res. 1992;590:277–84. [PubMed] 107. Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T. Effect of single intracerebroventricular injection of α-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol. 2000;10:129–32. [PubMed] 108. De La Garza R, Asnis GM. The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-α induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res. 2003;977:70–9. [PubMed] 109. De La Garza R, Asnis GM, Pedrosa E, et al. Recombinant human interferon-α does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog Neuropsychopharmacol Biol Psychiat. 2005;29:781–92. [PubMed] 110. Chesler DA, Reiss CS. The role of IFN-gamma in immune responses to viral infections of the central nervous system. Cytokine Growth Factor Rev. 2002;13:441–54. [PubMed] 111. Wunner WH, Bell J, Munro HN. The effect of feeding with a tryptophan-free amino acid mixture on rat-liver polysomes and ribosomal ribonucleic acid. Biochem J. 1966;101:417–28. [PubMed] 112. Wurtman RJ, Fernstrom JD. Control of brain neurotransmitter synthesis by precursor availability and nutritional state. Biochem Pharmacol. 1976;25:1691–6. [PubMed] 113. Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol. 2002;22:86–90. [PubMed] 114. Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiat. 2003;54:906–14. [PubMed] 115. Meyers CA. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol. 1999;461:75–81. [PubMed] 116. Saito K, Markey SP, Heyes MP. Chronic effects of y-interferon on quinolinic acid and indoleamine-2,3-dioxygenase in brain of C57BL6 mice. Brain Res. 1991;546:151–4. [PubMed] 117. Clement HW, Buschmann J, Rex S, et al. Effects of interferon-γ, interleukin-1β, and tumor necrosis factor-α on the serotonin metabolism in the nucleus raphe dorsalis of the rat. J Neural Transm. 1997;104:981–91. [PubMed] 118. Werner ER, Werner-Felmayer G, Wachter H. Tetrahydrobiopterin and cytokines. Proc Soc Exp Biol Med. 1993;203:1–12. [PubMed] 119. Bianchi M, Clavenna A, Bondiolotti GP, Ferrario P, Panerai AE. GM-CSF affects hypothalamic neurotransmitter levels in mice: involvement of interleukin-1. NeuroReport. 1997;10:3587–90. [PubMed] 120. Quan N, Herkenham M. Connecting cytokines and brain: a review of current issues. Histol Histopathol. 2002;17:273–88. [PubMed] 121. Dunn AJ. Mechanisms by which cytokines signal the brain. In: Clow A, Hucklebridge F, editors. Neurobiology of the immune system, international review of neurobiolog. Vol. 52. San Diego: Academic Press; 2002. pp. 43–65. [PubMed] 122. Rivier C. Influence of immune signals on the hypothalamic-pituitary axis of the rodent. Front Neuroendocrinol. 1995;16:151–82. [PubMed] 123. Matta SG, Singh J, Newton R, Sharp BM. The adrenocorticotropin response to interleukin-1β instilled into the rat median eminence depends on the local release of catecholamines. Endocrinology. 1990;127:2175–82. [PubMed] 124. McCoy JG, Matta SG, Sharp B. Prostaglandins mediate the ACTH response to interleukin-1-beta instilled into the hypothalamic median eminence. Neuroendocrinology. 1994;60:426–35. [PubMed] 125. Lee HY, Whiteside MB, Herkenham M. Area postrema removal abolishes stimulatory effects of intravenous interleukin-1β on hypothalamic-pituitary-adrenal axis activity and c-fos mRNA in the hypothalamic paraventricular nucleus. Brain Res Bull. 1998;46:495–503. [PubMed] 126. Banks WA, Ortiz L, Plotkin SR, Kastin AJ. Human interleukin (IL)1α, murine IL-1α and murine IL-1β are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther. 1991;259:988–96. [PubMed] 127. Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood–brain barrier. Neuroimmunomodulation. 1995;2:241–8. [PubMed] 128. Banks WA, Farr SA, La Scola ME, Morley JE. Intravenous human interleukin-1α impairs memory processing in mice: dependence on blood-brain barrier transport into posterior division of the septum. J Pharmacol Exp Ther. 2001;299:1–6. [PubMed] 129. Wan W, Wetmore L, Sorensen CM, Greenberg AH, Nance DM. Neural and biochemical mediators of endotoxin and stress-induced c-fos expression in the rat brain. Brain Res Bull. 1994;34:7–14. [PubMed] 130. Watkins LR, Wiertelak EP, Goehler LE, et al. Neurocircuitry of illness-induced hyperalgesia. Brain Res. 1994;639:283–99. [PubMed] 131. Bret-Dibat J-L, Bluthé R-M, Kent S, Kelley KW, Dantzer R. Lipopolysaccharide and interleukin-1 depress food-motivated behavior in mice by a vagal-mediated mechanism. Brain Behav Immun. 1995;9:242–6. [PubMed] 132. Watkins LR, Maier SF, Goehler LE. Cytokine-to-brain communication: a review & analysis of alternative mechanism. Life Sci. 1995;57:1011–26. [PubMed] 133. Goehler LE, Relton JK, Dripps D, et al. Vagal paraganglia bind biotinylated interleukin-1 receptor antagonist (IL-1ra) in the rat: a possible mechanism for immune-to-brain communication. Brain Res Bull. 1997;43:357–64. [PubMed]
134. Haour F, Ban E, Marquette C, Milon G, Fillion G. Brain Interleukin-1 receptors: mapping, characterization and modulation. In: Rothwell NJ, Dantzer RD, editors. Interleukin-1 in the brain. Oxford: Pergamon Press; 1992. pp. 13–25.
135. Takao T, Tracey DE, Mitchell WM, De Souza EB. Interleukin-1 receptors in mouse brain: characterization and neuronal localization. Endocrinology. 1990;127:3070–8. [PubMed] 136. Quan N, Whiteside M, Herkenham M. Time course and localization patterns of interleukin-1β messenger RNA expression in brain and pituitary after peripheral administration of lipopolysaccharide. Neuroscience. 1998;83:281–93. [PubMed] 137. Van Dam AM, Brouns M, Louisse S, Berkenbosch F. Appearance of interleukin 1 in macrophages and in ramified microglia in the brain of endotoxin-treated rats: a pathway for the induction of non-specific symptoms of sickness? Brain Res. 1992;588:291–6. [PubMed] 138. Bliss EL, Migeon CJ, Eik-Nes K, Sandberg AA, Samuels LT. The effects of insulin, histamine, bacterial pyrogen, and the antabuse-alcohol reaction upon the levels of 17-hydroxycorticosteroids in the peripheral blood of man. Metabolism. 1954;3:493–501. [PubMed] 139. Pohorecky LA, Wurtman RJ, Taam D, Fine J. Effects of endotoxin on monoamine metabolism in the rat. Proc Soc Exp Biol Med. 1972;140:739–46. [PubMed] 140. Mefford IN, Heyes MP. Increased biogenic amine release in mouse hypothalamus following immunological challenge: antagonism by indomethacin. J Neuroimmunol. 1990;27:55–61. [PubMed] 141. Masana MI, Heyes MP, Mefford IN. Indomethacin prevents increased catecholamine turnover in rat brain following systemic endotoxin challenge. Prog Neuro Psychopharmacol Biol Psychiat. 1990;14:609–21. [PubMed] 142. Lacosta S, Merali Z, Anisman H. Behavioral and neurochemical consequences of lipopolysaccharide in mice: anxiogenic-like effects. Brain Res. 1999;818:291–303. [PubMed] 143. Delrue C, Deleplanque B, Rouge-Pont F, Vitiello S, Neveu PJ. Brain monoaminergic, neuroendocrine, and immune responses to an immune challenge in relation to brain and behavioral lateralization. Brain Behav Immun. 1994;8:137–52. [PubMed] 144. Molina-Holgado F, Guaza C. Endotoxin administration induced differential neurochemical activation of the rat brain stem nuclei. Brain Res Bull. 1996;40:151–6. [PubMed] 145. Heyes MP, Quearry BJ, Markey SP. Systemic endotoxin increases L-tryptophan, 5-hydroxyindoleacetic acid, 3-hydroxykynurenine and quinolinic acid content of mouse cerebral cortex. Brain Res. 1989;491:173–9. [PubMed] 146. Lavicky J, Dunn AJ. Endotoxin administration stimulates cerebral catecholamine release in freely moving rats as assessed by microdialysis. J Neurosci Res. 1995;40:407–13. [PubMed] 147. Linthorst ACE, Flachskamm C, Holsboer F, Reul JMHM. Activation of serotonergic and noradrenergic neurotransmission in the rat hippocampus after peripheral administration of bacterial endotoxin: involvement of the cyclo-oxygenase pathway. Neuroscience. 1996;72:989–97. [PubMed] 148. Linthorst ACE, Flachskamm C, Müller-Preuss P, Holsboer F, Reul JMHM. Effect of bacterial endotoxin and interleukin-1β on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study. J Neurosci. 1995;15:2920–34. [PubMed] 149. Linthorst ACE, Flachskamm C, Holsboer F, Reul JMHM. Intraperitoneal administration of bacterial endotoxin enhances noradrenergic neurotransmission in the rat preoptic area: relationship with body temperature and hypothalamic–pituitary–adrenocortical axis activity. Eur J Neurosci. 1995;7:2418–30. [PubMed] 150. Borowski T, Kokkinidis L, Merali Z, Anisman H. Lipopolysaccharide, central in vivo amine variations, and anhedonia. NeuroReport. 1998;9:3797–802. [PubMed] 151. Smith T, Hewson AK, Quarrie L, Leonard JP, Cuzner ML. Hypothalamic PGE2 and cAMP production and adrenocortical activation following intraperitoneal endotoxin injection: in vivo microdialysis studies in Lewis and Fischer rats. Neuroendocrinology. 1994;59:396–405. [PubMed]
152. Beisel WR. Alterations in hormone production and utilization during infection. In: Powanda MC, Canonico PG, editors. Infections: the physiologic and metabolic responses of the host. Amsterdam: Elsevier/North-Holland Biomedical Press; 1981. pp. 147–72.
153. Kass EH, Finland M. Corticosteroids and infection. Adv Int Med. 1958;9:45–80. [PubMed] 154. Smith EM, Meyer WJ, Blalock JE. Virus-induced corticosterone in hypophysectomized mice: a possible lymphoid adrenal axis. Science. 1982;218:1311–2. [PubMed] 155. Silverman MN, Pearce BD, Biron CA, Miller AH. Immune modulation of the hypothalamic–pituitary–adrenal (HPA) axis during viral infection. Viral Immunol. 2005;18:41–78. [PMC free article] [PubMed] 156. Dunn AJ, Powell ML, Moreshead WV, Gaskin JM, Hall NR. Effects of Newcastle disease virus administration to mice on the metabolism of cerebral biogenic amines, plasma corticosterone, and lymphocyte proliferation. Brain Behav Immun. 1987;1:216–30. [PubMed] 157. Dunn AJ, Vickers SL. Neurochemical and neuroendocrine responses to Newcastle disease virus administration in mice. Brain Res. 1994;645:103–12. [PubMed] 158. Dunn AJ, Powell ML, Meitin C, Small PA. Virus infection as a stressor: influenza virus elevates plasma concentrations of corticosterone, and brain concentrations of MHPG and tryptophan. Physiol Behav. 1989;45:591–4. [PubMed] 159. Ben Hur T, Rosenthal J, Itzik A, Weidenfeld J. Adrenocortical activation by herpes virus: involvement of IL-1β and central noradrenergic system. NeuroReport. 1996;7:927–31. [PubMed] 160. Guo ZM, Qian CG, Peters CJ, Liu CT. Changes in platelet-activating factor, catecholamine, and serotonin concentrations in brain, cerebrospinal fluid, and plasma of Pichinde virus-infected guinea pigs. Lab Anim Sci. 1993;43:569–74. [PubMed] 161. Miller AH, Spencer RL, Pearce BD, et al. Effects of viral infection on corticosterone secretion and glucocorticoid receptor binding in immune tissues. Psychoneuroendocrinology. 1997;22:455–74. [PubMed] 162. Weidenfeld J, Wohlman A, Gallily R. Mycoplasma fermentans activates the hypothalamo-pituitary adrenal axis in the rat. NeuroReport. 1995;6:910–2. [PubMed]
163. Stone EA. Stress and catecholamines. In: Friedhoff AJ, editor. Catecholamines and behavior, neuropsychopharmacology. Vol. 2. New York: Plenum Press; 1975. pp. 31–72.
164. Dunn AJ, Kramarcy NR. Neurochemical responses in stress: relationships between the hypothalamic–pituitary–adrenal and catecholamine systems. In: Iversen LL, Iversen SD, Snyder SH, editors. Handbook of psychopharmacology. Vol. 18. New York: Plenum Press; 1984. pp. 455–515.
165. Kirby LG, Kreiss DS, Singh A, Lucki I. Effect of destruction of serotonin neurons on basal and fenfluramine-induced serotonin release in striatum. Synapse. 1995;20:99–105. [PubMed] 166. Hennet T, Ziltener HJ, Frei K, Peterhans E. A kinetic study of immune mediators in the lungs of mice infected with influenza A virus. J Immunol. 1992;149:932–9. [PubMed] 167. Dunn AJ. Effects of the interleukin-1 (IL-1) receptor antagonist on the IL-1- and endotoxin-induced activation of the HPA axis and cerebral biogenic amines in mice. Neuroimmunomodulation. 2000;7:36–45. [PubMed] 168. Swiergiel AH, Smagin GN, Johnson LJ, Dunn AJ. The role of cytokines in the behavioral responses to endotoxin and influenza virus infection in mice: effects of acute and chronic administration of the interleukin-1-receptor antagonist (IL-1ra) Brain Res. 1997;776:96–104. [PubMed] 169. Fantuzzi G, Zheng H, Faggioni R, et al. Effect of endotoxin in IL-1β-deficient mice. J Immunol. 1996;157:291–6. [PubMed] 170. Swiergiel AH, Dunn AJ. The roles of IL-1, IL-6 and TNFα in the feeding responses to endotoxin and influenza virus infection in mice. Brain Behav Immun. 1999;13:252–65. [PubMed] 171. Turnbull AV, Rivier C. Regulation of the HPA axis by cytokines. Brain Behav Immun. 1995;9:253–75. [PubMed] 172. Chuluyan H, Saphier D, Rohn WM, Dunn AJ. Noradrenergic innervation of the hypothalamus participates in the adrenocortical responses to interleukin-1. Neuroendocrinology. 1992;56:106–11. [PubMed] 173. Weidenfeld J, Abramsky O, Ovadia H. Evidence for the involvement of the central adrenergic system in interleukin 1-induced adrenocortical response. Neuropharmacology. 1989;28:1411–4. [PubMed] 174. Dunn AJ. Cytokine activation of the HPA axis. Ann NY Acad Sci. 2000;917:608–17. [PubMed]
175. Silverman MN, Pearce BD, Miller AH. Cytokines and HPA axis regulation. In: Kronfol Z, editor. Cytokines and mental health. Norwell, Mass: Kluwer; 2003. pp. 85–122.
176. Silverman MN, Miller AH, Biron CA, Pearce BD. Characterization of an interleukin-6 and adrenocorticotropin-dependent, immune-to-adrenal pathway during viral infection. Endocrinology. 2004;145:3580–9. [PubMed] 177. Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988;12:123–37. [PubMed] 178. Kent S, Bluthé R-M, Kelley KW, Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci. 1992;13:24–8. [PubMed]
179. Dantzer R, Bluthé R-M, Castanon N, et al. Cytokine effects on behavior. In: Ader R, Felten D, Cohen N, editors. Psychoneuroimmunology. San Diego, CA: Academic Press; 2001. pp. 703–27.
180. Larson SJ, Dunn AJ. Behavioral effects of cytokines. Brain Behav Immun. 2001;15:371–87. [PubMed] 181. Swiergiel AH, Smagin GN, Dunn AJ. Influenza virus infection of mice induces anorexia: comparison with endotoxin and interleukin-1 and the effects of indomethacin. Pharmacol Biochem Behav. 1997;57:389–96. [PubMed]
182. Cooper SJ, Clifton PG. Drug receptors subtypes and ingestive behaviour. London: Academic Press; 1996.
183. Swiergiel AH, Burunda T, Patterson B, Dunn AJ. Endotoxin- and interleukin-1-induced hypophagia are not affected by noradrenergic, dopaminergic, histaminergic and muscarinic antagonists. Pharmacol Biochem Behav. 1999;63:629–37. [PubMed] 184. Swiergiel AH, Dunn AJ. Lack of evidence for a role of serotonin in interleukin-1-induced hypophagia. Pharmacol Biochem Behav. 2000;65:531–7. [PubMed]
185. Dunn AJ. Effects of cytokines on cerebral neurotransmission and potential relationships to function. In: Kronfol Z, editor. Cytokines and mental health. Kluwer; Norwell, MA: 2003. pp. 55–83.
186. Hellerstein MK, Meydani SN, Meydani M, Wu K, Dinarello CA. Interleukin-1-induced anorexia in the rat. Influence of prostaglandins. J Clin Invest. 1989;84:228–35. [PMC free article] [PubMed] 187. Dunn AJ, Swiergiel AH. The role of cyclooxygenases in endotoxin-and interleukin-1-induced hypophagia. Brain Behav Immun. 2000;14:141–52. [PubMed] 188. Swiergiel AH, Dunn AJ. Distinct roles for cyclooxygenases 1 and 2 in interleukin-1-induced hypophagia. J Pharmacol Exp Ther. 2002;302:1031–6. [PubMed] 189. Ovadia H, Abramsky O, Weidenfeld J. Evidence for the involvement of the central adrenergic system in the febrile response induced by interleukin-1 in rats. J Neuroimmunol. 1989;25:109–16. [PubMed] 190. Bianchi M, Panerai AE. CRH and the noradrenergic system mediate the antinociceptive effects of central interleukin-1α in the rat. Brain Res Bull. 1995;36:113–7. [PubMed] 191. Hinze-Selch D, Pollmächer T. In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research. Brain Behav Immun. 2001;15:282–318. [PubMed] 192. de Beaurepaire R. Questions raised by the cytokine hypothesis of depression. Brain Behav Immun. 2002;16:610–7. [PubMed]
193. de Beaurepaire R, Swiergiel AH, Dunn AJ. Neuroimmune mediators: are cytokines mediators of depression. In: Licinio J, Wong M-L, editors. Biology of depression. Vol. 2. Weinheim: Wiley; 2005. pp. 557–81.
194. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res. 1996;711:163–74. [PubMed] 195. Charlton BG. The malaise theory of depression: major depressive disorder is sickness behavior and antidepressants are analgesic. Med Hypotheses. 2000;54:126–30. [PubMed] 196. Dantzer R, Wollman EE, Vitkovic L, Yirmiya R. Cytokines, stress, and depression. Adv Exp Biol Med. 1999;461:317–29. [PubMed] 197. Yirmiya R, Weidenfeld J, Pollak Y, et al. Cytokines, ‘Depression due to a general medical condition,’ and antidepressant drugs. Adv Exp Med Biol. 1999;461:283–316. [PubMed] 198. Sachar EJ. Corticosteroids in depressive illness: II. A longitudinal psychoendocrine study. Arch Gen Psychiatry. 1967;17:554–67. [PubMed] 199. Carroll BJ, Martin FIR, Davies B. Resistance to suppression by dexamethasone of plasma 11-OHCS levels in severe depressive illness. Br Med J. 1968;3:285–7. [PMC free article] [PubMed] 200. Holsboer F, Gerken A, Stalla GK, Muller OA. Blunted aldosterone and ACTH release after human CRH administration in depressed patients. Am J Psychiatry. 1987;144:229–31. [PubMed] 201. Nemeroff CB. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry. 1996;1:336–42. [PubMed] 202. Owens MJ, Nemeroff CB. The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. In: Chadwick DJ, Marsh J, Ackrill K, editors. Corticotropin-releasing factor, Ciba foundation symposium. Vol. 172. London: Wiley; 1993. pp. 296–316. [PubMed] 203. Koslow SH, Maas JW, Bowden CL, Davis JM, Hanin I, Javaid J. CSF and urinary biogenic amines and metabolites in depression and mania. Arch Gen Psychiatry. 1983;40:999–1010. [PubMed] 204. Wong ML, Kling MA, Munson PJ, et al. Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci USA. 2000;97:325–30. [PubMed] 205. Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what we can learn from animal studies? Neurosci Biobehav Rev. 2005;29:891–909. [PubMed] 206. Zorrilla EP, Luborsky L, McKay JR, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001;15:199–226. [PubMed] 207. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 1999;40:171–6. [PubMed] 208. Krueger JM, Majde JA. Microbial products and cytokines in sleep and fever regulation. Crit Rev Immmunol. 1995;14:355–79. [PubMed] 209. Engelborghs S, De Brabander M, De Crée J, et al. Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type. Neurochem Int. 1999;334:523–30. [PubMed]